Abstract

  To find an immediately applicable drug for the treatment of COVID-19 positive patients, a plausible life cycle of this virus is proposed from the analysis of a few case reports. Based on this proposal and symptomatic similarities, a few common drug-molecules are tested as a protease inhibitor and RNA dependent RNA polymerase (RdRp) inhibitor of SARS-CoV-2 virus using COVID-19 Docking Server. It is observed that anisotine and vasicoline of Justicia adhatoda and Pemirolast are very good inhibitors. As all these three compounds are market available drugs, an immediate clinical trial is plausible which may lead to the golden success against the present pandemic. We prescribed different drugs for different purposes and stages of viral infection.

Keywords: COVID-19; Structure of SARS-CoV-2; Infection Mechanism of COVID-19; Model Drugs for COVID-19; Docking Study

References

1. World Health Organization. “Coronavirus disease 2019 (COVID-19): situation report” (2020): 51.
2. Liu Y., et al. “The reproductive number of COVID- 19 is higher compared to SARS coronavirus”. Journal of Travel Medicine (2020): taaa21.
3. Pan F., et al. “Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia”. Radiology (2020): 200370.
4. Wu Z and McGoogan JM. “Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention”. The Journal of the American Medical Association (2020).
5. Fang Y., et al. “Sensitivity of chest CT for COVID-19: comparison to RT-PCR”. Radiology (2020): 200432.
6. Ai T., et al. “Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases”. Radiology (2020): 200642.
7. Shi H., et al. “Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study”. The Lancet Infectious Diseases (2020).
8. Lan L., et al. “Positive RT-PCR test results in patients recovered from COVID-19”. The Journal of the American Medical Association (2020).
9. Yan R., et al. “Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2”. Science (2020).
10. Guarner J. “Three Emerging Coronaviruses in Two Decades: The Story of SARS, MERS, and Now COVID-19 (2020).
11. Kim JM., et al. “Identification of Coronavirus Isolated from a Patient in Korea with COVID-19”. Osong Public Health and Research Perspectives1 (2020): 3.
12. He Q., et al. “Single Cell RNA Sequencing Analysis of Human Kidney Reveals the Presence of ACE2 Receptor: A Potential Pathway of COVID- 19 Infection (2020).
13. Bai Y., et al. “Presumed asymptomatic carrier transmission of COVID-19”. The Journal of the American Medical Association (2020).
14. Chen H., et al. “Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records”. The Lancet10226 (2020): 809-815.
15. Liu W and Li H. “COVID-19 Disease: ORF8 and Surface Glycoprotein Inhibit Heme Metabolism by Binding to Porphyrin”. Chem Rxiv (2020).
16. Smith M and Smith JC. “Repurposing Therapeutics for COVID-19: Supercomputer-Based Docking to the SARS-CoV-2 Viral Spike Protein and Viral Spike Protein-Human ACE2 Interface”. Chem Rxiv (2020).
17. Kong R., et al. “COVID-19 Docking Server: An interactive server for docking small molecules, peptides and antibodies against potential targets of COVID-19 (2003).

Citation

Citation: Abhrajit Bag and Arijit Bag. “Search for Natural Alkaloids as SARS-CoV-2 Proteas and RdRp Inhibitors: A Docking-Based Study". Acta Scientific Pharmaceutical Sciences 4.11 (2020): 77-81.

Copyright

Copyright: © 2020 Abhrajit Bag and Arijit Bag. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.